VIRI vs. CYCN, HEPA, LGVN, TFFP, MTEM, ADIL, AKTX, ASLN, BFRI, and GRTX
Should you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Cyclerion Therapeutics (CYCN), Hepion Pharmaceuticals (HEPA), Longeveron (LGVN), TFF Pharmaceuticals (TFFP), Molecular Templates (MTEM), Adial Pharmaceuticals (ADIL), Akari Therapeutics (AKTX), ASLAN Pharmaceuticals (ASLN), Biofrontera (BFRI), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical preparations" industry.
Virios Therapeutics (NASDAQ:VIRI) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, Cyclerion Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 0 mentions for Virios Therapeutics. Cyclerion Therapeutics' average media sentiment score of 0.86 beat Virios Therapeutics' score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.
Virios Therapeutics' return on equity of -110.15% beat Cyclerion Therapeutics' return on equity.
Virios Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.
9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 11.7% of Virios Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cyclerion Therapeutics has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cyclerion Therapeutics received 32 more outperform votes than Virios Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Virios Therapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.
Summary
Cyclerion Therapeutics beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Virios Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virios Therapeutics Competitors List
Related Companies and Tools
